Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
Sylvie Dejager,1 Anja Schweizer,2 James E Foley31Novartis Pharma SAS, Rueil Malmaison, France; 2Novartis Pharma AG, Basel, Switzerland; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAAbstract: The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, as monotherapy...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-05-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | http://www.dovepress.com/evidence-to-support-the-use-of-vildagliptin-monotherapy-in-the-treatme-a9919 |